Clinical Trial Update: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab given alone versus the standard chemotherapy with radiation after surgery for recurrent head and neck squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING